Cyclin E2 (phospho Thr392) Polyclonal Antibody

Catalog No: #13935

Package Size: #13935-1 50ul #13935-2 100ul

Signalway Antibody
Orders: order@signalwayantibody.com
Support: tech@signalwayantibody.com

Description

Product Name	Cyclin E2 (phospho Thr392) Polyclonal Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Applications	IF/ICC,ELISA
Species Reactivity	Human,Mouse
Specificity	Phospho-Cyclin E2 (T392) Polyclonal Antibody detects endogenous levels of Cyclin E2 protein only when phosphorylated at T392.
Immunogen Description	The antiserum was produced against synthesized peptide derived from human Cyclin E2 around the phosphorylation site of Thr392. AA range:355-404
Conjugates	Unconjugated
Other Names	CCNE2; G1/S-specific cyclin-E2
Accession No.	Swiss Prot:O96020GeneID:9134
Calculated MW	46kd
Concentration	1 mg/ml
Formulation	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage	-20°C/1

Application Details

Immunofluorescence: 1/200 - 1/1000. ELISA: 1/10000. Not yet tested in other applications.

Background

cyclin E2(CCNE2) Homo sapiens The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK2. This cyclin has been shown to specifically interact with CIP/KIP family of CDK inhibitors, and plays a role in cell cycle G1/S transition. The expression of this gene peaks at the G1-S phase and exhibits a pattern of tissue specificity distinct from that of cyclin E1. A significantly increased expression level of this gene was observed in tumor-derived cells. [provided by RefSeq, Jul 2008],